Fulcrum Capital LLC Buys 162 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Fulcrum Capital LLC grew its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,124 shares of the medical instruments supplier’s stock after purchasing an additional 162 shares during the period. Fulcrum Capital LLC’s holdings in West Pharmaceutical Services were worth $2,438,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in WST. LGT Group Foundation purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $68,854,000. Liontrust Investment Partners LLP purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $64,196,000. Findlay Park Partners LLP lifted its holdings in shares of West Pharmaceutical Services by 30.6% during the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock valued at $236,281,000 after purchasing an additional 139,800 shares during the last quarter. Iron Triangle Partners LP purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $47,381,000. Finally, ProShare Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 13.9% during the 1st quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock valued at $198,117,000 after purchasing an additional 61,247 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $286.44 on Thursday. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The stock has a fifty day moving average price of $299.72 and a 200-day moving average price of $323.06. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The firm has a market cap of $20.78 billion, a PE ratio of 40.75, a P/E/G ratio of 10.21 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s revenue was down 6.9% on a year-over-year basis. During the same quarter last year, the business earned $2.11 EPS. Equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at $443,400. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.53% of the stock is currently owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.